Valneva SE
PAR:VLA
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2.036
5.502
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one VLA stock under the Base Case scenario is 6.24 EUR. Compared to the current market price of 2.036 EUR, Valneva SE is Undervalued by 67%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Valneva SE
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for VLA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Valneva SE
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Valneva SE
Balance Sheet Decomposition
Valneva SE
Current Assets | 269.2m |
Cash & Short-Term Investments | 131.4m |
Receivables | 30.5m |
Other Current Assets | 107.2m |
Non-Current Assets | 197.4m |
PP&E | 156.5m |
Intangibles | 24.2m |
Other Non-Current Assets | 16.7m |
Current Liabilities | 102.5m |
Accounts Payable | 8.5m |
Accrued Liabilities | 41.5m |
Other Current Liabilities | 52.5m |
Non-Current Liabilities | 197.8m |
Long-Term Debt | 187.1m |
Other Non-Current Liabilities | 10.7m |
Earnings Waterfall
Valneva SE
Revenue
|
229.4m
EUR
|
Cost of Revenue
|
-140.5m
EUR
|
Gross Profit
|
88.9m
EUR
|
Operating Expenses
|
-33.6m
EUR
|
Operating Income
|
55.3m
EUR
|
Other Expenses
|
-38m
EUR
|
Net Income
|
17.3m
EUR
|
Free Cash Flow Analysis
Valneva SE
EUR | |
Free Cash Flow | EUR |
Valneva showcased robust Q1 2024 results, achieving a net profit nearing €60 million and maintaining €175 million in cash. Product sales remained steady at €32.1 million, aligning with internal forecasts. Significant pipeline advancements include the chikungunya vaccine, now generating initial revenues following favorable CDC recommendations. The Phase III Lyme disease study progresses on schedule, and the Zika vaccine advances into Phase I. The company reaffirmed its 2024 guidance of €160-180 million in product sales and expects sustained profitability from 2025, excluding Lyme-related revenues, which are anticipated in early 2027.
What is Earnings Call?
VLA Profitability Score
Profitability Due Diligence
Valneva SE's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
Score
Valneva SE's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
VLA Solvency Score
Solvency Due Diligence
Valneva SE's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Score
Valneva SE's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VLA Price Targets Summary
Valneva SE
According to Wall Street analysts, the average 1-year price target for VLA is 7.758 EUR with a low forecast of 2.879 EUR and a high forecast of 11.55 EUR.
Dividends
Current shareholder yield for VLA is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
VLA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Valneva SE is a biotech company. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 722 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Contact
IPO
Employees
Officers
The intrinsic value of one VLA stock under the Base Case scenario is 6.24 EUR.
Compared to the current market price of 2.036 EUR, Valneva SE is Undervalued by 67%.